Findings

What do systematic reviews say?

8 questions · 8 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 12.5%GRADE not reported 4 · 50%Very low 2 · 25%Low 1 · 12.5%Moderate 0 · 0%High 0 · 0%

Prebiotics and anti‐inflammatory therapy vs anti‐inflammatory therapy

Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis

The review found no eligible studies for this question.

1 finding from 1 review

Prebiotics for induction and maintenance of remission in ulcerative colitis 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Briakinumab vs placebo

Withdrawals due to adverse events · people with moderate to severe Crohn's disease in remission

Briakinumab showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).

1 finding from 1 review

Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.82 [0.04, 16.34]
1 study · 104 participants
Low

Inulin and oligofructose 15 g vs inulin and oligofructose 7.5 g daily

Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis

It is very uncertain whether inulin and oligofructose 15 g changes withdrawals due to adverse events (9 weeks) compared with inulin and oligofructose 7.5 g daily (very low certainty).

1 finding from 1 review

Prebiotics for induction and maintenance of remission in ulcerative colitis 2024 · Cochrane Headline outcomes only
RR 0.53 [0.11, 2.5]
1 study · 31 participants
Very low

Summary of findings table ‐ Topical capsaicin vs placebo

Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…

1 finding from 1 review

Pharmacological interventions for pain in patients with temporomandibular disorders 2010 · Cochrane All outcomes
4 weeks
Three participants from the topical capsaicin group withdrew from the study by Winocur et al 2000 due to the severity of the burning sensation and redness.
1 study · 30 participants
GRADE not reported

Oral gabapentin vs placebo

Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…

1 finding from 1 review

Pharmacological interventions for pain in patients with temporomandibular disorders 2010 · Cochrane All outcomes
12 weeks
Four of the participants withdrew from the study by Kimos et al 2007 due to adverse effects, but neither the type of adverse effect nor the trial group was specified.
1 study · 44 participants
GRADE not reported

Oral glucosamine hydrochloride/chondroitin sulphate vs placebo

Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…

1 finding from 1 review

Pharmacological interventions for pain in patients with temporomandibular disorders 2010 · Cochrane All outcomes
3 months
Two allergic reactions and one severe abdominal pain led to three withdrawals from the intervention group in the study by Nguyen et al 2001.
1 study · 45 participants
GRADE not reported

Oral clonazepam (benzodiazepine) vs placebo

Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…

1 finding from 1 review

Pharmacological interventions for pain in patients with temporomandibular disorders 2010 · Cochrane All outcomes
60 days
One participant in the clonazepam group withdrew from the study by Harkins et al 1991 due to severe headache.
1 study · 20 participants
GRADE not reported

Prebiotic vs placebo

Withdrawals due to adverse events · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)

It is very uncertain whether prebiotics changes withdrawals due to adverse events (14 days to 2 or 3 months) compared with placebo (very low certainty).

1 finding from 1 review

Prebiotics for induction and maintenance of remission in ulcerative colitis 2024 · Cochrane Headline outcomes only
RR 2.73 [0.51, 14.55]
2 studies · 31 participants
Very low